Patients with cirrhosis who have controlled, stable disease and normal liver function are generally eligible for the New Crown vaccine, provided that they clearly explain this to the vaccinating physician and the consulting physician and obtain consent. Patients with uncontrolled, active or even deteriorating disease, or with other serious complications, are usually not recommended for vaccination. Cirrhosis is a chronic, progressive, diffuse disease of liver tissue caused by hepatitis B virus infection. If the disease continues to progress and is not effectively controlled, resulting in serious impairment of liver function, such as when generalized skin jaundice, lower limb edema, liver palms, spider nevus, ascites, etc. have already appeared, vaccination with the New Crown vaccine may adversely affect the metabolic function of the liver, further aggravate the disease, and may have a negative impact on the effectiveness of the New Crown vaccine. Patients in the active stage of cirrhosis are unstable and may also cause other complications, such as high fever, bleeding and easy infection, which may induce adverse reactions when vaccinated, so vaccination is also not recommended. It is recommended that patients with cirrhosis who have a strong desire to be vaccinated consult with the relevant vaccination site about the specific situation and clearly inform the hospital professionals about the extent of their condition, and if necessary, they may need to complete relevant tests to clarify whether they can be vaccinated.